Modality
Fusion Protein
MOA
CD3xCD20
Target
GPRC5D
Pathway
Fibrosis
PTSD
Development Pipeline
Preclinical
~Jun 2012
→ ~Sep 2013
Phase 1
~Dec 2013
→ ~Mar 2015
Phase 2
~Jun 2015
→ ~Sep 2016
Phase 3
~Dec 2016
→ ~Mar 2018
NDA/BLA
~Jun 2018
→ ~Sep 2019
Approved
Dec 2019
→ May 2029
ApprovedCurrent
NCT05759755
1,233 pts·PTSD
2020-01→2029-05·Completed
NCT03909558
733 pts·PTSD
2019-12→TBD·Terminated
1,966 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-05-063.1y awayPh3 Readout· PTSD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2029-05-06 · 3.1y away
PTSD
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05759755 | Approved | PTSD | Completed | 1233 | Biomarker |
| NCT03909558 | Approved | PTSD | Terminated | 733 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |